Nivo 240 mg and Rela 80 mg per vial, OPDIVO 10 mg/mL concentrate for solution for infusion.
CA224-098
Phase 3 small_molecule active
Quick answer
Nivo 240 mg and Rela 80 mg per vial, OPDIVO 10 mg/mL concentrate for solution for infusion. for Participants with completely resected Stage III or Stage IV melanoma is a Phase 3 program (small_molecule) at Bristol-Myers Squibb / Pfizer EEIG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bristol-Myers Squibb / Pfizer EEIG
- Indication
- Participants with completely resected Stage III or Stage IV melanoma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active